# A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

> **NCT02261493** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 787 (actual)

## Conditions studied

- Facial Rhytides
- Glabellar Rhytides

## Interventions

- **BIOLOGICAL:** OnabotulinumtoxinA
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02261493
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-27
- **Primary completion:** 2015-06-03
- **Final completion:** 2016-04-20
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261493, "A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02261493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*